{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:43:11Z","timestamp":1792687391906,"version":"4.5.0"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005669","name":"Funda\u00e7\u00e3o de Apoio \u00e0 Pesquisa do Estado da Para\u00edba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejmech.2025.117500","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T16:39:36Z","timestamp":1741711176000},"page":"117500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Targeting cysteine protease B to discover antileishmanial drugs: Directions and advances"],"prefix":"10.1016","volume":"289","author":[{"given":"\u00c9ric","family":"de Oliveira Rios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonaly Lima","family":"Albino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Olimpio de Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-4336","authenticated-orcid":false,"given":"Igor Jos\u00e9 dos Santos","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117500_bib1","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2174\/092986733116240214143511","article-title":"Targeting cysteine and serine proteases to discover new drugs against neglected tropical diseases","volume":"31","author":"dos Santos Nascimento","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009278","article-title":"Scoping review of neglected tropical disease interventions and health promotion: a framework for successful ntd interventions as evidenced by the literature","volume":"15","author":"Ackley","year":"2021","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib3","article-title":"Insights to design new drugs against human african trypanosomiasis targeting rhodesain using covalent docking, molecular Dynamics simulations, and MM-PBSA calculations","volume":"20","author":"Nascimento","year":"2024","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.ejmech.2025.117500_bib4","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.2174\/1568026623666221122121330","article-title":"Advances in computational methods to discover new NS2B-NS3 inhibitors useful against dengue and zika viruses","volume":"22","author":"dos Santos Nascimento","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejmech.2018.06.040","article-title":"Current advances in drug discovery for Chagas disease","volume":"155","author":"Scarim","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib6","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2174\/0113816128267517231010061552","article-title":"Pharmacokinetic limitations to overcome and enable K777 as a potential drug against Chagas disease","volume":"29","author":"De Souza","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2025.117500_bib7","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2174\/1568026621666210331152702","article-title":"Cruzain and rhodesain inhibitors: last decade of advances in seeking for new compounds against American and african trypanosomiases","volume":"21","author":"dos Santos Nascimento","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011449","article-title":"A systematic review on maternal-to-infant transfer of drugs through breast milk during the treatment of malaria, tuberculosis, and neglected tropical diseases","volume":"17","author":"Ojara","year":"2023","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1573406417666210216154428","article-title":"Synthesis, antileishmanial activity and in silico studies of aminoguanidine hydrazones (AGH) and thiosemicarbazones (TSC) against leishmania chagasi amastigotes","volume":"18","author":"de Aquino","year":"2022","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129876","article-title":"Synthesis and activity of benzimidazole N-Acylhydrazones against Trypanosoma cruzi, Leishmania amazonensis and Leishmania infantum","author":"Ramos","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117500_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejmech.2016.03.022","article-title":"Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents","volume":"115","author":"Rashid","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib12","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.4c00089","article-title":"Targeting leishmania promastigotes and amastigotes forms through amino acids and peptides: a promising therapeutic strategy","author":"Registre","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106885","article-title":"Differential structure and immunomodulatory functions of lipophosphoglycan between Leishmania spp","volume":"268","author":"Teufel","year":"2024","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejmech.2025.117500_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012054","article-title":"Whole cell reconstructions of Leishmania mexicana through the cell cycle","volume":"20","author":"Hair","year":"2024","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2025.117500_bib15","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.3390\/cimb44050141","article-title":"Subtilisin of leishmania amazonensis as potential druggable target: subcellular localization, in vitro leishmanicidal activity and molecular docking of PF-429242, a subtilisin inhibitor","volume":"44","author":"Gomes","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117500_bib16","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/AAC.04742-14","article-title":"Epoxy-\u03b1-Lapachone has in vitro and in vivo anti-leishmania (leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite","volume":"59","author":"Souza-Silva","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.117500_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.lfs.2019.01.015","article-title":"Leishmanicidal therapy targeted to parasite proteases","volume":"219","author":"Machado","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.117500_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2021.106182","article-title":"Prediction of potential cysteine synthase inhibitors of Leishmania braziliensis and Leishmania major parasites by computational screening","volume":"225","author":"T\u00e9llez","year":"2022","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2025.117500_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128289","article-title":"In vitro anti-Leishmania activity and molecular docking of spiro-acridine compounds as potential multitarget agents against Leishmania infantum","volume":"49","author":"Almeida","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117500_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001626","article-title":"In vitro and in vivo activity of a palladacycle complex on leishmania (leishmania) amazonensis","volume":"6","author":"Paladi","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012156","article-title":"Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis","volume":"18","author":"Fern\u00e1ndez","year":"2024","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/17460441.2016.1195945","article-title":"Drug target identification in protozoan parasites","volume":"11","author":"M\u00fcller","year":"2016","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117500_bib23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2174\/1570180819666220405225817","article-title":"The new era of drug discovery: the power of computer-aided drug design (CADD)","volume":"19","author":"Nascimento","year":"2022","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2025.117500_bib24","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3390\/microorganisms11122845","article-title":"Drug discovery for cutaneous leishmaniasis: a review of developments in the past 15 years","volume":"11","author":"Corman","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2025.117500_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejmech.2018.10.022","article-title":"Leishmania treatment and prevention: natural and synthesized drugs","volume":"160","author":"Bekhit","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115927","article-title":"Synthetic product-based approach toward potential antileishmanial drug development","volume":"263","author":"Pal","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.929493","article-title":"Discovery of leishmania druggable serine proteases by activity-based protein profiling","volume":"13","author":"Porta","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117500_bib28","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3390\/pathogens10121608","article-title":"Challenges and tools for in vitro leishmania exploratory screening in the drug development process: an updated review","volume":"10","author":"Cohen","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.ejmech.2025.117500_bib29","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.2174\/1389557522666220404085858","article-title":"Strategies in medicinal chemistry to discover new hit compounds against ebola virus: challenges and perspectives in drug discovery","volume":"22","author":"dos Santos Nascimento","year":"2022","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib30","series-title":"Cysteine Proteases","first-page":"181","author":"Grzonka","year":"2007"},{"key":"10.1016\/j.ejmech.2025.117500_bib31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/microorganisms11061397","article-title":"Roles of cysteine proteases in biology and pathogenesis of parasites","volume":"11","author":"Yang","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2025.117500_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/9789811457791120050004","article-title":"Molecular modeling applied to design of cysteine protease inhibitors \u2013 a powerful tool for the identification of hit compounds against neglected tropical diseases","author":"Jos\u00e9 dos Santos Nascimento","year":"2020","journal-title":"Front. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.mib.2004.06.010","article-title":"Cysteine peptidases as virulence factors of Leishmania","volume":"7","author":"Mottram","year":"2004","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.ejmech.2025.117500_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116461","article-title":"Targeting the cysteine biosynthesis pathway in microorganisms: mechanism, structure, and drug discovery","volume":"271","author":"Tao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(01)00290-0","article-title":"Substrate specificity of recombinant cysteine proteinase, CPB, of Leishmania mexicana","volume":"116","author":"Alves","year":"2001","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2025.117500_bib36","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1128\/IAI.71.6.3190-3195.2003","article-title":"Expression of multiple CPB genes encoding cysteine proteases is required for leishmania mexicana virulence in vivo","volume":"71","author":"Denise","year":"2003","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2025.117500_bib37","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.3390\/biom12121903","article-title":"Novel selective and low-toxic inhibitor of LmCPB2.8\u0394CTE (CPB) one important cysteine protease for leishmania virulence","volume":"12","author":"Moreira","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.117500_bib38","doi-asserted-by":"crossref","first-page":"10497","DOI":"10.1021\/acs.jmedchem.9b00683","article-title":"Can cysteine protease cross-class inhibitors achieve selectivity?","volume":"62","author":"Cianni","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib39","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1021\/acs.jcim.0c00815","article-title":"Is structure-based drug design ready for selectivity optimization?","volume":"60","author":"Albanese","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.117500_bib40","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1021\/jm2010332","article-title":"Rational approaches to improving selectivity in drug design","volume":"55","author":"Huggins","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib41","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.2174\/0929867327666200812215852","article-title":"Drug repurposing: a strategy for discovering inhibitors against emerging viral infections","volume":"28","author":"dos Santos Nascimento","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib42","article-title":"TNF-\u03b1 Inhibitors from natural compounds: an overview, CADD approaches, and their exploration for anti-inflammatory agents","volume":"24","author":"dos Santos Nascimento","year":"2021","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.ejmech.2025.117500_bib43","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.2174\/0929867329666220317122948","article-title":"Computer-Aided drug design of anti-inflammatory agents targeting microsomal prostaglandin E2 synthase-1 (mPGES-1)","volume":"29","author":"dos Santos Nascimento","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116396","article-title":"Privileged small molecules against neglected tropical diseases: a perspective from structure activity relationships","volume":"271","author":"Abbasi Shiran","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1039\/D1MD00362C","article-title":"Current leishmaniasis drug discovery","volume":"13","author":"Pinheiro","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib46","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/med.22005","article-title":"Experimental structure based drug design (SBDD) applications for anti\u2010leishmanial drugs: a paradigm shift?","volume":"44","author":"Mar\u00edn","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.117500_bib47","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2174\/092986712799828300","article-title":"Leishmaniasis: prevention, parasite detection and treatment","volume":"19","author":"Kobets","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ad.2021.02.008","article-title":"Leishmaniasis cut\u00e1nea y mucocut\u00e1nea","volume":"112","author":"Abad\u00edas-Granado","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ejmech.2025.117500_bib49","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13071-017-2028-5","article-title":"The history of leishmaniasis","volume":"10","author":"Steverding","year":"2017","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.ejmech.2025.117500_bib50","doi-asserted-by":"crossref","first-page":"750","DOI":"10.12688\/f1000research.11120.1","article-title":"Leishmaniasis: a review","volume":"6","author":"Torres-Guerrero","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.ejmech.2025.117500_bib51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/pathogens12020297","article-title":"Unusual observations in leishmaniasis\u2014an overview","volume":"12","author":"Yadav","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.ejmech.2025.117500_bib52","first-page":"1","article-title":"Immune responses in leishmaniases: an overview","volume":"7","author":"Costa-Da-silva","year":"2022","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib53","article-title":"Epidemiology and clinical features of parasitic disease Leishmaniasis. A case study from Pakistan","author":"khan","year":"2024","journal-title":"M\u00e9dica Sur"},{"key":"10.1016\/j.ejmech.2025.117500_bib54","unstructured":"Leishmaniasis, (n.d.). https:\/\/www.who.int\/health-topics\/leishmaniasis#tab=tab_1 (accessed June 22, 2020)."},{"key":"10.1016\/j.ejmech.2025.117500_bib55","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3390\/microorganisms12071317","article-title":"Epidemiology and genetic characterization of leishmania RNA virus in leishmania (viannia) spp. isolates from cutaneous leishmaniasis endemic areas in Panama","volume":"12","author":"Bonilla","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2025.117500_bib56","first-page":"76","article-title":"Spatio-temporal analysis and clinical-epidemiological characterization of visceral leishmaniasis in maranh\u00e3o, Brazil, from 2009 to 2020","volume":"9","author":"Amaral","year":"2024","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/CLEP.S44267","article-title":"Epidemiology of visceral leishmaniasis","author":"Ready","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.ejmech.2025.117500_bib58","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/pathogens13060455","article-title":"Global distribution of canine visceral leishmaniasis and the role of the dog in the epidemiology of the disease","volume":"13","author":"Vilas-Boas","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.ejmech.2025.117500_bib59","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7625.1000207","article-title":"Sandfly and leishmaniasis: a review","volume":"6","author":"Ghazanfar","year":"2016","journal-title":"J. Ecosyst. Ecography"},{"key":"10.1016\/j.ejmech.2025.117500_bib60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40475-021-00232-7","article-title":"A review of leishmaniasis: current knowledge and future directions","volume":"8","author":"Mann","year":"2021","journal-title":"Curr. Trop. Med. Reports"},{"key":"10.1016\/j.ejmech.2025.117500_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2015.03.017","article-title":"Vaccines for visceral leishmaniasis: a review","volume":"422","author":"Jain","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejmech.2025.117500_bib62","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00436-021-07139-2","article-title":"Leishmaniasis: where are we and where are we heading?","volume":"120","author":"Sasidharan","year":"2021","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejmech.2025.117500_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116365","article-title":"Cysteine proteases as potential targets for anti-trypanosomatid drug discovery","volume":"46","author":"Judice","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib64","article-title":"Prevalence and associated factors of asymptomatic leishmaniasis: a systematic review and meta-analysis","volume":"81","author":"Bin Mannan","year":"2021","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.ejmech.2025.117500_bib65","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.actatropica.2017.05.022","article-title":"Atypical presentations of cutaneous leishmaniasis: a systematic review","volume":"172","author":"Meireles","year":"2017","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2025.117500_bib66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/labmed\/lmac134","article-title":"Review of the clinical presentation, pathology, diagnosis, and treatment of leishmaniasis","volume":"54","author":"Mathison","year":"2023","journal-title":"Lab. Med."},{"key":"10.1016\/j.ejmech.2025.117500_bib67","article-title":"Nanomaterials for diagnosis, treatment, and prevention of human cutaneous leishmaniasis: a review","volume":"12","author":"Maza Vega","year":"2023","journal-title":"Open"},{"key":"10.1016\/j.ejmech.2025.117500_bib68","first-page":"430","article-title":"Systematic review of treatment failure and clinical relapses in leishmaniasis from a multifactorial perspective: clinical aspects, factors associated with the parasite and host","volume":"8","author":"Santos","year":"2023","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115609","article-title":"The role of natural anti-parasitic guided development of synthetic drugs for leishmaniasis","volume":"258","author":"Pal","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/microorganisms9040691","article-title":"Leishmania protein kinases: important regulators of the parasite life cycle and molecular targets for treating leishmaniasis","volume":"9","author":"Efstathiou","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2025.117500_bib71","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.actatropica.2017.04.029","article-title":"Application of nanotechnology in treatment of leishmaniasis: a Review","volume":"172","author":"Akbari","year":"2017","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2025.117500_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012735","article-title":"Progress in antileishmanial drugs: mechanisms, challenges, and prospects","volume":"19","author":"Zhang","year":"2025","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2022.102739","article-title":"Protease inhibitors as a potential agent against visceral Leishmaniasis: a review to inspire future study","volume":"27","author":"Sreedharan","year":"2023","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib74","first-page":"1","article-title":"Drug targets in leishmania, J. Parasit","volume":"34","author":"Chawla","year":"2010","journal-title":"Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib75","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2174\/1389450122666210809090909","article-title":"Molecular modeling targeting transmembrane serine protease 2 (TMPRSS2) as an alternative drug target against coronaviruses","volume":"23","author":"dos Santos Nascimento","year":"2022","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2025.117500_bib76","article-title":"Targeting SmCB1: perspectives and insights to design antischistosomal drugs","volume":"31","author":"Nascimento","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib77","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2174\/1568026622666220321124452","article-title":"Medicinal chemistry of inhibitors targeting resistant bacteria","volume":"22","author":"Monteiro","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115550","article-title":"Exploring N-myristoyltransferase as a promising drug target against parasitic neglected tropical diseases","volume":"258","author":"Nascimento","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib79","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.3390\/molecules25081924","article-title":"Targeting trypanothione reductase, a key enzyme in the redox trypanosomatid metabolism, to develop new drugs against leishmaniasis and trypanosomiases","volume":"25","author":"Battista","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117500_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.622286","article-title":"An overview on the therapeutics of neglected infectious diseases\u2014leishmaniasis and Chagas diseases","volume":"9","author":"J","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib81","doi-asserted-by":"crossref","unstructured":"B.B. Das, A. Ganguly, H.K. Majumder, DNA Topoisomerases of Leishmania: The Potential Targets for Anti-Leishmanial Therapy, in: Drug Targets Kinetoplastid Parasites, Springer New York, New York, NY, n.d.: pp. 103\u2013115. https:\/\/doi.org\/10.1007\/978-0-387-77570-8_9.","DOI":"10.1007\/978-0-387-77570-8_9"},{"key":"10.1016\/j.ejmech.2025.117500_bib82","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/0118715206269722231121173311","article-title":"Overview of the new bioactive heterocycles as targeting topoisomerase inhibitors useful against colon cancer","volume":"24","author":"Santos","year":"2024","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006512","article-title":"Cysteine proteases in protozoan parasites","volume":"12","author":"Siqueira-Neto","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib84","series-title":"Handb. Proteolytic Enzym.","first-page":"1923","article-title":"Leishmania CPA, CPB and CPC cysteine proteases","author":"Myburgh","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117500_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116365","article-title":"Cysteine proteases as potential targets for anti-trypanosomatid drug discovery","volume":"46","author":"Judice","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib86","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0169-4758(90)90189-B","article-title":"Cysteine proteinases of parasitic protozoa","volume":"6","author":"North","year":"1990","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.ejmech.2025.117500_bib87","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1021\/acs.jmedchem.4c01180","article-title":"Innovative drug discovery research by pharmaceutical companies in India and China","volume":"67","author":"Kumar","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/13543776.2024.2327299","article-title":"Therapeutic cysteine protease inhibitors: a patent review (2018\u2013present)","volume":"34","author":"Barchielli","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.117500_bib89","author":"Abhithaj"},{"key":"10.1016\/j.ejmech.2025.117500_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116213","article-title":"Computer-aided design of 1,4-naphthoquinone-based inhibitors targeting cruzain and rhodesain cysteine proteases","volume":"41","author":"Silva","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pharmthera.2017.06.004","article-title":"Targeting cysteine proteases in trypanosomatid disease drug discovery","volume":"180","author":"Ferreira","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117500_bib92","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/biom13091339","article-title":"Recent advances in SARS-CoV-2 main protease inhibitors: from Nirmatrelvir to future perspectives","volume":"13","author":"Citarella","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.117500_bib93","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2174\/1570180819666220106110133","article-title":"Repurposing FDA-approved drugs targeting SARS-CoV2 3CL pro : a study by applying virtual screening, molecular Dynamics, MM-PBSA calculations and covalent docking","volume":"19","author":"dos Santos Nascimento","year":"2022","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2025.117500_bib94","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1021\/cr950025u","article-title":"Cysteine proteases and their inhibitors","volume":"97","author":"Otto","year":"1997","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.117500_bib95","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2174\/1381612023394124","article-title":"Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators","volume":"8","author":"Turk","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2025.117500_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00107","article-title":"Cysteine proteases: modes of activation and future prospects as pharmacological targets","volume":"7","author":"Verma","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117500_bib97","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.ijpara.2004.10.003","article-title":"Cysteine proteases of malaria parasites","volume":"34","author":"Rosenthal","year":"2004","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ejmech.2025.117500_bib98","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijbiomac.2021.03.016","article-title":"Novel biotechnological formulations of cysteine proteases, immobilized on chitosan. Structure, stability and activity","volume":"180","author":"Holyavka","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2025.117500_bib99","article-title":"The power of molecular Dynamics simulations and their applications to discover cysteine protease inhibitors","volume":"23","author":"dos Santos Nascimento","year":"2023","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.18388\/abp.2004_3519","article-title":"Modes of inhibition of cysteine proteases","volume":"51","author":"Rzychon","year":"2004","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.ejmech.2025.117500_bib101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cccn.2003.12.016","article-title":"Cysteine proteases as disease markers","volume":"342","author":"Berdowska","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2025.117500_bib102","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0968-0896(99)00008-5","article-title":"Cysteine protease inhibitors as chemotherapy for parasitic infections","volume":"7","author":"McKerrow","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib103","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/156802606776287081","article-title":"Inhibitors of cysteine proteases","volume":"6","author":"Vicik","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib104","article-title":"The diverse roles of cysteine proteases in parasites and their suitability as drug targets","volume":"12","author":"McKerrow","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(01)00438-8","article-title":"Cysteine proteases of parasitic organisms","volume":"120","author":"Sajid","year":"2002","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2025.117500_bib106","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/138161207780162962","article-title":"Emerging roles of cysteine cathepsins in disease and their potential as drug targets","volume":"13","author":"Vasiljeva","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2025.117500_bib107","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1039\/b924677k","article-title":"Cysteine proteases as targets for metal-based drugs","volume":"2","author":"Fricker","year":"2010","journal-title":"Metallomics"},{"key":"10.1016\/j.ejmech.2025.117500_bib108","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0169-4758(98)01241-1","article-title":"Leishmania cysteine proteinases: virulence factors in quest of a function","volume":"14","author":"Descoteaux","year":"1998","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.ejmech.2025.117500_bib109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2199-6-3","article-title":"Role of Leishmania (Leishmania) chagasi amastigote cysteine protease in intracellular parasite survival: studies by gene disruption and antisense mRNA inhibition","volume":"6","author":"Mundodi","year":"2005","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117500_bib110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0166-1280(00)00799-5","article-title":"Molecular modeling study on a Leishmania cysteine proteinase","volume":"539","author":"Alves","year":"2001","journal-title":"J. Mol. Struct. THEOCHEM"},{"key":"10.1016\/j.ejmech.2025.117500_bib111","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.4049\/jimmunol.161.12.6794","article-title":"Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response","volume":"161","author":"Alexander","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.117500_bib112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-6851(00)00377-7","article-title":"Identification of Leishmania major cysteine proteinases as targets of the immune response in humans","volume":"113","author":"Rafati","year":"2001","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2025.117500_bib113","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.4049\/jimmunol.170.4.1746","article-title":"The leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses","volume":"170","author":"Pollock","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.117500_bib114","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2958.2006.05274.x","article-title":"Cysteine peptidases CPA and CPB are vital for autophagy and differentiation in Leishmania mexicana","volume":"61","author":"Williams","year":"2006","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2025.117500_bib115","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1242\/jcs.113.22.4035","article-title":"Processing and trafficking of cysteine proteases in Leishmania mexicana","volume":"113","author":"Brooks","year":"2000","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2025.117500_bib116","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1017\/S0031182099006435","article-title":"Analysis of the roles of cysteine proteinases of Leishmania mexicana in the host\u2013parasite interaction","volume":"121","author":"Frame","year":"2000","journal-title":"Parasitology"},{"key":"10.1016\/j.ejmech.2025.117500_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2021.126784","article-title":"Cysteine proteases: battling pathogenic parasitic protozoans with omnipresent enzymes","volume":"249","author":"Rawat","year":"2021","journal-title":"Microbiol. Res."},{"key":"10.1016\/j.ejmech.2025.117500_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106623","article-title":"Curative efficacy of purified serine protease inhibitor PTF3 from potato tuber in experimental visceral leishmaniasis","volume":"85","author":"Paik","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2025.117500_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001236","article-title":"C-terminal domain deletion enhances the protective activity of cpa\/cpb loaded solid lipid nanoparticles against leishmania major in BALB\/c mice","volume":"5","author":"Doroud","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2025.117500_bib120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4155\/fmc.10.17","article-title":"Protease inhibitors as prophylaxis against leishmaniasis: new hope from the major surface protease Gp63","volume":"2","author":"Olivier","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib121","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.actatropica.2012.11.012","article-title":"Identification of Tunisian Leishmania spp. by PCR amplification of cysteine proteinase B (cpb) genes and phylogenetic analysis","volume":"125","author":"Chaouch","year":"2013","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2025.117500_bib122","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1756-3305-5-160","article-title":"Proteinases as virulence factors in Leishmania spp. infection in mammals","volume":"5","author":"Silva-Almeida","year":"2012","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.ejmech.2025.117500_bib123","first-page":"87","article-title":"Computational analysis of cysteine proteases (clan CA, family C1) of leishmania major to find potential epitopic regions, genomics","volume":"7","author":"Saffari","year":"2009","journal-title":"Proteomics Bioinformatics."},{"key":"10.1016\/j.ejmech.2025.117500_bib124","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.molbiopara.2005.07.004","article-title":"Specific negative charges in cysteine protease isoforms of Leishmania mexicana are highly influential on the substrate binding and hydrolysis","volume":"144","author":"Judice","year":"2005","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2025.117500_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115743","article-title":"Crystal structure of Leishmania mexicana cysteine protease B in complex with a high-affinity azadipeptide nitrile inhibitor","volume":"28","author":"Ribeiro","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109649","article-title":"Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development","volume":"115","author":"Gupta","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2025.117500_bib127","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/med.21475","article-title":"Proteases and protease inhibitors in infectious diseases","volume":"38","author":"Agbowuro","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.117500_bib128","series-title":"Challenges Solut. Against Visc. Leishmaniasis","first-page":"81","article-title":"Leishmania proteomics: insight into diagnostics and vaccine development","author":"Maurya","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117500_bib129","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1128\/AAC.01430-05","article-title":"Aziridine-2,3-Dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity","volume":"50","author":"Ponte-Sucre","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.117500_bib130","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1128\/AAC.00327-10","article-title":"Aziridine-2,3-Dicarboxylate-Based cysteine cathepsin inhibitors induce cell death in leishmania major associated with accumulation of debris in autophagy-related lysosome-like vacuoles","volume":"54","author":"Schurigt","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.117500_bib131","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/AAC.00426-15","article-title":"Development of a new antileishmanial aziridine-2,3-dicarboxylate-based inhibitor with high selectivity for parasite cysteine proteases","volume":"60","author":"Schad","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.117500_bib132","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejmech.2018.07.012","article-title":"New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8","volume":"156","author":"Fey","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib133","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.biopha.2015.08.030","article-title":"Benzophenone derivatives as cysteine protease inhibitors and biological activity against Leishmania(L.) amazonensis amastigotes","volume":"75","author":"de Almeida","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.117500_bib134","doi-asserted-by":"crossref","first-page":"30628","DOI":"10.1039\/C6RA05557E","article-title":"Targeting of the Leishmania mexicana cysteine protease CPB2.8\u0394CTE by decorated fused benzo[b]thiophene scaffold","volume":"6","author":"Scala","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.117500_bib135","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/cbdd.13326","article-title":"Discovery of benzimidazole\u2010based Leishmania mexicana cysteine protease CPB 2.8\u0394 CTE inhibitors as potential therapeutics for leishmaniasis","volume":"92","author":"De Luca","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.117500_bib136","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.exppara.2019.04.001","article-title":"Dipeptidyl nitrile derivatives have cytostatic effects against Leishmania spp. promastigotes","volume":"200","author":"Quilles","year":"2019","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ejmech.2025.117500_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127439","article-title":"Synthesis and matched molecular pair analysis of covalent reversible inhibitors of the cysteine protease CPB","volume":"30","author":"Matos","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117500_bib138","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/cmdc.201000265","article-title":"\u03b1\u2010Ketoheterocycles as inhibitors of leishmania mexicana cysteine protease CPB","volume":"5","author":"Steert","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117500_bib139","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/S0968-0896(98)80022-9","article-title":"Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors","volume":"6","author":"Scheidt","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib140","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202302415","article-title":"5\u2010Arylidene\u20102,4\u2010thiazolidinediones as cysteine protease inhibitors against leishmania donovani","volume":"8","author":"Sharma","year":"2023","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2025.117500_bib141","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/ph16020204","article-title":"ACW-02 an acridine triazolidine derivative presents antileishmanial activity mediated by DNA interaction and immunomodulation","volume":"16","author":"Albino","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117500_bib142","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/jmf.2010.0018","article-title":"Natural products from Garcinia brasiliensis as leishmania protease inhibitors","volume":"14","author":"Pereira","year":"2011","journal-title":"J. Med. Food"},{"key":"10.1016\/j.ejmech.2025.117500_bib143","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.exppara.2015.05.016","article-title":"Natural products as inhibitors of recombinant cathepsin L of Leishmania mexicana","volume":"156","author":"de Sousa","year":"2015","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ejmech.2025.117500_bib144","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/microorganisms11010225","article-title":"Flavonoid derivatives as new potent inhibitors of cysteine proteases: an important step toward the design of new compounds for the treatment of leishmaniasis","volume":"11","author":"Louren\u00e7o","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2025.117500_bib145","article-title":"Modeling and docking of cysteine protease-A (CPA) of leishmania donovani","year":"2017","journal-title":"J. Appl. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2025.117500_bib146","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1021\/jm0493717","article-title":"Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database","volume":"47","author":"Desai","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib147","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1021\/jm0505765","article-title":"Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory","volume":"49","author":"Desai","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077460","article-title":"Identification of semicarbazones, thiosemicarbazones and triazine nitriles as inhibitors of leishmania mexicana cysteine protease CPB","volume":"8","author":"Schr\u00f6der","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117500_bib149","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1021\/cc0001102","article-title":"Combinatorial library of peptide isosters based on Diels\u2212Alder reactions: identification of novel inhibitors against a recombinant cysteine protease from leishmania mexicana","volume":"3","author":"Graven","year":"2001","journal-title":"J. Comb. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib150","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/jm0110901","article-title":"Solid-phase library synthesis, screening, and selection of tight-binding reduced peptide bond inhibitors of a recombinant leishmania m exicana cysteine protease B","volume":"45","author":"Hilaire","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib151","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/cc020085v","article-title":"Combinatorial library of peptidotriazoles: identification of [1,2,3]-Triazole inhibitors against a recombinant leishmania m exicana cysteine protease","volume":"6","author":"Torn\u00f8e","year":"2004","journal-title":"J. Comb. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib152","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","article-title":"Cysteine cathepsins: from structure, function and regulation to new frontiers","volume":"1824","author":"Turk","year":"2012","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"key":"10.1016\/j.ejmech.2025.117500_bib153","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/acs.biochem.8b00315","article-title":"The taxonomy of covalent inhibitors","volume":"57","author":"Tuley","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.117500_bib154","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4155\/fmc.10.21","article-title":"Strategies for discovering and derisking covalent, irreversible enzyme inhibitors","volume":"2","author":"Johnson","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117500_bib155","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2174\/1381612023394197","article-title":"Cysteine proteases of malaria parasites: targets for chemotherapy","volume":"8","author":"Rosenthal","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2025.117500_bib156","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14728222.2019.1685981","article-title":"The proteasome as a target for protozoan parasites","volume":"23","author":"Xie","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2025.117500_bib157","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00044-023-03065-3","article-title":"An update on the discovery and development of reversible covalent inhibitors","volume":"32","author":"Faridoon","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.117500_bib158","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.3390\/microorganisms9122500","article-title":"Antileishmanial drug discovery and development: time to reset the model?","volume":"9","author":"Ol\u00edas-Molero","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2025.117500_bib159","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12951-021-00853-0","article-title":"Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight","volume":"19","author":"Jamshaid","year":"2021","journal-title":"J. Nanobiotechnol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500265X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500265X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:26:23Z","timestamp":1749057983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500265X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":159,"alternative-id":["S022352342500265X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117500","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cysteine protease B to discover antileishmanial drugs: Directions and advances","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117500"}}